drugset / Trial / NCT06716216
A Study of BGM0504 in Participants with Type 2 Diabetes
Phase 3
Recruiting
537 enrolled
BrightGene Bio-Medical Technology Co., Ltd.
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
Timeline
- Start
- 2024-11-29
- Primary completion
- 2026-03-20
- Completion
- 2026-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGM0504 | Unknown | 5 mg | Subcutaneous |
| Subject | BGM0504 | Unknown | 10 mg | Subcutaneous |
| Comparator | Semaglutide | Peptide | 1 mg | Subcutaneous |